Novotech

Medtech Company IME Technologies Moves to New and Much Larger R & D And Production Facility in Waalre, The Netherlands

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

MGS Advances Healthcare Product Development with Hybrid Tooling

MGS, a healthcare-focused contract development and manufacturing organization, has...

Daewoong and Chime Biologics Partner for Biosimilar Push

Chime Biologics and Daewoong Pharmaceutical have entered into a...

Aragen Backs Renaissance Rare Disease Therapy Launch

Contract research, development, and manufacturing organization (CRDMO) Aragen has...
- Advertisement -

Medical technology company IME Technologies, developer, producer and scientific partner in the field of biomedical electro spinning processes and equipment, has moved its operations from Geldrop to a significantly larger facility in Waalre with effect from 26 March.

IME’s state-of-the-art technology enables scientists to develop medical implants that help the human body to repair itself, such as heart valves, blood vessels, nerves, tendons, skin and bone. IME is a world leader in this field. Later this year (September 2018) IME Technologies will officially open the new facility during an event themed ‘The future of regenerative medicine’.

In the new IME building at the Van Dijklaan in Waalre, the company will have the ability to, according to the highest standards, not only produce its electro spinning machines autonomously, but also the actual extracellular matrices or scaffolds for the intended medical implants. These are developed by IME in close collaboration with various partners. The company has a growing number of customers and partners worldwide in industry, science and medical institutes.

IME’s technological solutions are able to mimic the natural human extracellular matrix for implants in the human body in nanometer format, applying specific polymers. Human cells attach to this matrix leading to new body tissue. This is in contrast to implants of traditional structures, which are seen as foreign and therefore can be rejected or lead to scar tissue.

About IME Technologies
IME Technologies develops and implements electro spin processes and equipment for the manufacturing of medical devices for (regenerative) medicine. Electro spinning is a flexible process for producing extremely thin fibres and structures that have excellent properties for use in regenerating human tissue. IME Technologies has developed unique electro spin technology for the reproducible and scalable production of electro spun material under medical conditions. Customers include industry, scientists and institutions.

World Pharma Today brings together the global pharmaceutical industry โ€” from R&D leaders and regulatory affairs professionals to manufacturers and distribution executives โ€” through trusted editorial, market intelligence, and digital engagement.

Our 2026 Media Pack offers integrated solutions to reach your audience:

  • Magazine & Digital Editions Showcase your brand within premium pharmaceutical industry coverage read by executives and decision - makers worldwide.
  • Industry Insights & Reports Align with data - driven analysis, trend reports, and regional roundups across the global pharmaceutical and life sciences value chain.
  • Brand Authority & Credibility Position your company as a thought leader through expert commentary, interviews, and special features.

Latest stories

Related stories

MGS Advances Healthcare Product Development with Hybrid Tooling

MGS, a healthcare-focused contract development and manufacturing organization, has...

Daewoong and Chime Biologics Partner for Biosimilar Push

Chime Biologics and Daewoong Pharmaceutical have entered into a...

Aragen Backs Renaissance Rare Disease Therapy Launch

Contract research, development, and manufacturing organization (CRDMO) Aragen has...

Aragen Achieves Daretabart Commercial-scale GMP Production

Aragen, a global leader in Contract Research, Development, and...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป